Protocol Ledger

NCT07052097 · Phase II · COMPLETED

Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis

Interventional Phase II clinical trial protocol NCT07052097 sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-31 Enrollment: 136 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07052097
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)136 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07052097
Protocol FieldVerified Registry Value
NCT IdentifierNCT07052097
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment136 participants (ACTUAL)
Registered Start Date2025-07-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI